186
Participants
Start Date
December 15, 2017
Primary Completion Date
July 31, 2021
Study Completion Date
September 30, 2021
Dolutegravir 50 mg
Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
Efavirenz-based regimens
Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
Fundação Bahiana de Infectologia/SEI, Salvador
Universidade Federal do Rio de Janeiro, Rio de Janeiro
Hospital de Clinicas de Porto Alegre, Porto Alegre
Fundação Bahiana de Infectologia
OTHER